Previous 10 | Next 10 |
2024-01-25 09:45:00 ET Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for rare diseases or, at least, for conditions with severe un...
2024-01-25 06:14:55 ET Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. ...
2024-01-24 04:31:39 ET Summary Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystrophy. The company's FDA-approved products, includin...
2024-01-22 17:47:39 ET Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to an analyst's considerable price target raise. Sarepta's gain tr...
2024-01-22 13:43:30 ET Summary Sarepta's ELEVIDYS faces a critical FDA decision; an expanded label could significantly widen market reach, targeting all DMD patients. Strong Q3 performance with impressive revenue and EPS; financial health shows robust short-term standing but long-...
2024-01-20 10:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A drastic shift in inv...
2024-01-16 23:01:41 ET Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. ...
2024-01-16 10:41:01 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call P...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that screening is underway in Study SRP-9003-301. Also known as EMERGENE, Study 9003-301 is a Phase 3, multi-national, open-label study of SRP-9003 (bidridistrogene xeboparvovec) ...
2024-01-10 10:30:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for SRPT on January 10, 2024 11:00AM ET. The previous analyst recommendation was Underperform. SRPT was trading at $117.6 at issue of the analyst recommendation. The overall analyst consensus :...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
2024-06-26 10:06:00 ET When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer 's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.2% to $126.57 on volume of 604,432,871 shares American Rebel Holdings Inc. (AREB) rose 152.5% to $0.76 on volume of 367,740,589 shares Sirius XM Holdings Inc. (SIRI) rose 1.0% to $2.93 on volume of 329...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is one of today's top gainers. The company's shares have moved 34.64% on the day to $166.22. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies...